{"id":475030,"date":"2020-03-19T11:04:01","date_gmt":"2020-03-19T11:04:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=475030"},"modified":"2020-03-19T11:04:01","modified_gmt":"2020-03-19T11:04:01","slug":"mucopolysaccharidosis-type-i-market-insights-epidemiology-and-market-forecast2028","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/mucopolysaccharidosis-type-i-market-insights-epidemiology-and-market-forecast2028_475030.html","title":{"rendered":"Mucopolysaccharidosis Type I – Market Insights, Epidemiology, and Market Forecast-2028"},"content":{"rendered":"
\"Mucopolysaccharidosis<\/a><\/div>\n
DelveInsight’s “Mucopolysaccharidosis Type I – Market Insights, Epidemiology, and Market Forecast-2028” report delivers an in-depth understanding of the Mucopolysaccharidosis I, historical and forecasted epidemiology as well as the Mucopolysaccharidosis I market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n

DelveInsight launched its new report on Mucopolysaccharidosis Type  I – Market Insights, Epidemiology, and Market Forecast-2028<\/a><\/p>\n

DelveInsight’s “Mucopolysaccharidosis Type  I – Market Insights, Epidemiology, and Market Forecast-2028″<\/strong> report delivers an in-depth understanding of the Mucopolysaccharidosis I , historical and forecasted epidemiology as well as the Mucopolysaccharidosis I market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Mucopolysaccharidosis type I (MPS-I or Hurler syndrome) is heterogeneous, debilitating disorder and the severity of symptoms varies widely. Historically, the range of most-to-least severe forms are as follows: Hurler syndrome (MPS I-H), Hurler-Scheie syndrome (MPS I-H\/S), and Scheie syndrome (MPS I-S).<\/strong><\/p>\n

The key facts of the report:
<\/strong>1. Mucopolysaccharidosis Type I prevalence in England and Wales over the period 1981 to 2003 was 1.07\/100,000 births and within ± 5% of estimates reported in several studies that examined reasonably large populations
2. Mucopolysaccharidosis Type I tends to affect males and females equally with an incidence of about 1 in 100,000 live births<\/p>\n

Key benefits of the report:
<\/strong>1. Mucopolysaccharidosis Type I market report covers a descriptive overview and comprehensive insight of the Mucopolysaccharidosis Type I epidemiology and Mucopolysaccharidosis Type I market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Mucopolysaccharidosis Type I market report provides insights on the current and emerging therapies.
3. Mucopolysaccharidosis Type I market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Mucopolysaccharidosis Type I market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Mucopolysaccharidosis Type I market.<\/p>\n

Request for sample pages:<\/strong> https:\/\/www.delveinsight.com\/sample-request\/mucopolysaccharidosis-i-market<\/a><\/p>\n

\"\"<\/strong><\/p>\n

The key players in Mucopolysaccharidosis Type I market are:
<\/strong>1. Magenta Therapeutics
2. ArmaGen
3. REGENXBIO
And many others<\/p>\n

Drugs covered in Mucopolysaccharidosis Type I treatment market are:<\/strong>
1. Valanafusp alfa
2. RGX-121
3. MGTA-456
And many others<\/p>\n

Table of contents:
<\/strong>1. Report Introduction
2. Mucopolysaccharidosis Type I Market Overview at a Glance
3. Mucopolysaccharidosis Type I Disease Background and Overview
4. Mucopolysaccharidosis Type I Epidemiology and Patient Population (7MM)
5. Mucopolysaccharidosis Type I Country- Wise Epidemiology
5.1. United States
5.2. Germany
5.3. France
5.4. Italy
5.5. Spain
5.6. United Kingdom
5.7. Japan
6. Mucopolysaccharidosis Type I Treatments & Medical Practices
7. Mucopolysaccharidosis Type I Emerging Therapies
7.1. Key Cross Competition
7.2. Valanafusp alfa: ArmaGen
7.3. MGTA-456: Magenta Therapeutics
7.4. RGX-121: Regenxbio
8. Mucopolysaccharidosis Type I Market Size
8.1. Key Findings
8.2. Total 7MM Mucopolysaccharidosis Type I Market Analysis
9. 7MM: Country-Wise Market Analysis
9.1. United States Market Size
9.2. Germany Market Size
9.3. France Market Size
9.4. United Kingdom Market Size
9.5. Spain Market Size
9.6. Italy Market Size
9.7. Japan Market Size
10. Market Drivers
11. Market Barrier
12. Mucopolysaccharidosis Type I Report Methodology
13. DelveInsight Capabilities
14. Disclaimer
15. About DelveInsight<\/p>\n

Download a free sample report<\/strong> @<\/strong> https:\/\/www.delveinsight.com\/sample-request\/mucopolysaccharidosis-i-market<\/a><\/p>\n

Related reports: <\/strong><\/p>\n

Mucopolysaccharidosis Type II – Epidemiology Forecast to 2030<\/span><\/a><\/p>\n

 <\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 9193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight’s “Mucopolysaccharidosis Type I – Market Insights, Epidemiology, and Market Forecast-2028” report delivers an in-depth understanding of the Mucopolysaccharidosis I, historical and forecasted epidemiology as well as the Mucopolysaccharidosis I market trends in the United States, EU5 (Germany, Spain, Italy, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-475030","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/475030","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=475030"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/475030\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=475030"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=475030"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=475030"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}